Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$254.77-2.4%$221.27$184.63▼$261.64$461.26B0.38.34 million shs8.22 million shsJNJJohnson & Johnson$259.31-1.4%$233.72$154.21▼$263.10$633.19B0.248.38 million shs6.77 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-2.34%+0.36%+11.90%+23.55%+34.44%JNJJohnson & Johnson-1.22%+0.41%+11.38%+8.74%+66.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$254.77-2.4%$221.27$184.63▼$261.64$461.26B0.38.34 million shs8.22 million shsJNJJohnson & Johnson$259.31-1.4%$233.72$154.21▼$263.10$633.19B0.248.38 million shs6.77 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-2.34%+0.36%+11.90%+23.55%+34.44%JNJJohnson & Johnson-1.22%+0.41%+11.38%+8.74%+66.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.84Moderate Buy$256.670.74% UpsideJNJJohnson & Johnson 2.74Moderate Buy$257.13-0.84% DownsideCurrent Analyst Ratings BreakdownLatest JNJ and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026JNJJohnson & Johnson HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$290.007/6/2026ABBVAbbVie HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$300.007/6/2026ABBVAbbVie Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$240.00 ➝ $265.006/26/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$270.006/26/2026JNJJohnson & Johnson GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$266.00 ➝ $270.006/23/2026ABBVAbbVie Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform6/23/2026ABBVAbbVie Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/23/2026ABBVAbbVie Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$265.00 ➝ $273.006/23/2026ABBVAbbVie Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$298.006/22/2026ABBVAbbVie Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$260.006/15/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B7.36$14.78 per share17.24($1.83) per share-139.22JNJJohnson & Johnson$94.19B6.63$13.92 per share18.63$33.85 per share7.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03125.5015.890.865.79%-576.45%13.39%7/31/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6529.9820.582.5821.83%32.60%13.29%7/15/2026 (Estimated)Latest JNJ and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2026Q2 2026ABBVAbbVie$3.79N/AN/AN/A$16.77 billionN/A7/15/2026Q2 2026JNJJohnson & Johnson$2.83N/AN/AN/A$25.01 billionN/A4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.922.72%+6.80%340.89%53 YearsJNJJohnson & Johnson$5.362.07%+5.25%61.97%64 YearsLatest JNJ and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/18/2026ABBVAbbViequarterly$1.733.19%7/15/20267/15/20268/14/20264/14/2026JNJJohnson & Johnsonquarterly$1.342.33%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68JNJJohnson & Johnson0.461.030.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableJNJ and ABBV HeadlinesRecent News About These CompaniesJohnson & Johnson (NYSE:JNJ) Stock Price Down 1.4% - Here's WhyJuly 6 at 5:19 PM | marketbeat.com3 Healthcare ETFs to Own in a Choppy Stock MarketJuly 6 at 3:43 PM | finance.yahoo.comDouble Your Retirement Income in a Decade. Here’s How.July 6 at 3:43 PM | 247wallst.comWhy Johnson & Johnson (JNJ) is a Great Dividend Stock Right NowJuly 6 at 12:45 PM | zacks.comJ&J's MedTech Segment Eyes Another Strong Quarter in Q2July 6 at 12:00 PM | zacks.comFTSE 100 Live: Stocks slide despite airlines and defence gains, Microsoft slashes jobsJuly 6 at 12:00 PM | proactiveinvestors.comJohnson & Johnson Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallJuly 6 at 7:11 AM | benzinga.comJohnson & Johnson $JNJ Stock Holdings Increased by New York State Teachers Retirement SystemJuly 6 at 5:11 AM | marketbeat.comPrivate Advisor Group LLC Raises Holdings in Johnson & Johnson $JNJJuly 6 at 5:11 AM | marketbeat.comPeregrine Asset Advisers Inc. Cuts Position in Johnson & Johnson $JNJJuly 6 at 4:55 AM | marketbeat.comStrs Ohio Sells 42,784 Shares of Johnson & Johnson $JNJJuly 6 at 4:55 AM | marketbeat.comFjarde AP Fonden Fourth Swedish National Pension Fund Acquires 419,769 Shares of Johnson & Johnson $JNJJuly 6 at 3:36 AM | marketbeat.comElevation Point Wealth Partners LLC Grows Position in Johnson & Johnson $JNJJuly 6 at 3:36 AM | marketbeat.comFideuram Intesa Sanpaolo Private Banking S.P.A. Increases Position in Johnson & Johnson $JNJJuly 6 at 3:35 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by Boston Trust Walden CorpJuly 6 at 3:35 AM | marketbeat.comHeritage Investors Management Corp Lowers Stock Position in Johnson & Johnson $JNJJuly 6 at 3:35 AM | marketbeat.comJohnson & Johnson (JNJ) Unveils New IMAAVY Data With Broader Reach In ViewJuly 5 at 6:37 PM | finance.yahoo.comJohnson & Johnson (JNJ) Is One Of Jim Cramer’s Top Performing 2026 StocksJuly 5 at 8:35 AM | finance.yahoo.comHealthcare Stocks Worth Watching - July 4thJuly 5 at 5:17 AM | americanbankingnews.comJohnson & Johnson $JNJ Position Cut by Pzena Investment Management LLCJuly 5 at 4:55 AM | marketbeat.comVision Capital Management Inc. Cuts Stock Position in Johnson & Johnson $JNJJuly 5 at 4:55 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJNJ and ABBV Company DescriptionsAbbVie NYSE:ABBV$254.77 -6.30 (-2.41%) Closing price 07/6/2026 03:59 PM EasternExtended Trading$256.85 +2.08 (+0.82%) As of 05:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Johnson & Johnson NYSE:JNJ$259.31 -3.73 (-1.42%) Closing price 07/6/2026 03:59 PM EasternExtended Trading$260.82 +1.51 (+0.58%) As of 05:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
